Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-A01083-54 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Following the COVID-related health crisis, nasofibroscopic sampling could no longer be carried out
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective monocentric study of patients with systemic sclerosis disease.
The primary outcome is to define the prevalence of olfactory disorders (hyposmia and anosmia) in systemic sclerosis disease.
The secondary outcomes are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| systemic sclerosis patients population | Other | All the patients with systemic sclerosis disease followed in day-care in a tertiary hospital are eligible to be enrolled in the study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| olfactory testing with specific odorants (localisation and identification) | Diagnostic Test | Olfactory testing : ETOC (European Test of Olfactory capabilities) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patient with hyposmia defined by a ETOC (European Test of Olfactory Capabilities) score strictly inferior to 27 points | The European Test of Olfactory Capabilities is an olfactory test based on standardized odorants.A composite score evaluates the ability of the patients to define odors localisation and odors identification.The maximum global score is 32 points, the minimum is 0 point. The localisation ability score is rated from 0 to 16 points; The identification score is rated from 0 to 16 points. An hyposmia is defined by a global score strictly inferior to 27 points. | once time, Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patient with anosmia defined by a ETOC (European Test of Olfactory Capabilities) score strictly inferior to10 points | The European Test of Olfactory Capabilities is an olfactory test based on standardized odorants. A composite score evaluates the ability of the patients to define odors localisation and odors identification. The maximum global score is 32 points, the minimum is 0 point. The localisation ability score is rated from 0 to 16 points; The identification score is rated from 0 to 16 points. An anosmia is defined by an global score strictly inferior to 10 points. |
Not provided
Inclusion Criteria:
Exclusion Criteria :
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Launay, MD,PhD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hop Claude Huriez Chu Lille | Lille | 59037 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25424576 | Background | Amital H, Agmon-Levin N, Shoenfeld N, Arnson Y, Amital D, Langevitz P, Balbir Gurman A, Shoenfeld Y. Olfactory impairment in patients with the fibromyalgia syndrome and systemic sclerosis. Immunol Res. 2014 Dec;60(2-3):201-7. doi: 10.1007/s12026-014-8573-5. | |
| 29444467 | Result | Bombini MF, Peres FA, Lapa AT, Sinicato NA, Quental BR, Pincelli ASM, Amaral TN, Gomes CC, Del Rio AP, Marques-Neto JF, Costallat LTL, Fernandes PT, Cendes F, Rittner L, Appenzeller S. Olfactory function in systemic lupus erythematosus and systemic sclerosis. A longitudinal study and review of the literature. Autoimmun Rev. 2018 Apr;17(4):405-412. doi: 10.1016/j.autrev.2018.02.002. Epub 2018 Feb 11. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D045743 | Scleroderma, Diffuse |
| ID | Term |
|---|---|
| D012595 | Scleroderma, Systemic |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
The study is single-group epidemiologic study, without any control group.
Not provided
Not provided
Not provided
Not provided
|
| once time, Baseline |
| Percentage of patients with an unilateral Lund Kennedy score of more than 3 points. | Evaluation of nasal mucosa inflammation status is based on Lund-Kennedy endoscopic score. The Lund Kennedy score ranged from 0 to 8 points for each nasal fossa. It evaluates oedema, discharge, the presence of polyps and crusting, that can be seen through nasal fibroscopy. A score strictly under 3 points on each side is considered as non pathologic whereas a score equal or over 3 points on each side is pathological. A higher score means a worse outcome. | once time, Baseline |
| Measurement of systemic sclerosis disease activity with Medsger Score | Medsger Score estimates disease involvement of each organ (heart, vessels, skin, brain, kidney, gut, muscle, joint and loss of weight,) ranging from 0 to 4 (0: normal, 1: mild, 2: moderate, 3: severe, 4: terminal). The score ranges from 0 to 36 points.A higher score means a worse outcome. | once time, Baseline |
| Correlation between global olfactory score measured with ETOC score and systemic sclerosis disease activity measured with Medsger Score | The ETOC score ranges from 0 to 32 points ( as previously described ).A higher score means a better outcome. Medsger score ranges from 0 to 36 points. A higher score means a worse outcome. | once time, Baseline |
| Correlation between global olfactory score measured with ETOC score and skin involvement severity measured with Rodnan score. | The ETOC score ranges from 0 to 32 points ( as previously described ). A higher score means a better outcome. The Rodnan score measured skin thickness (0 : normal, 1 : mild, 2: moderate, 3: severe) on 17 different sites. A global score between 0 point to 51 points is established.A higher score means a worse outcome | once time, Baseline |
| Correlation between global olfactory score measured with ETOC score and systemic sclerosis disease activity measured with Health Assessment Questionnaire (HAQ) score | The ETOC score ranges from 0 to 32 points (as previously described ). A higher score means a better outcome. The Health Assessment Questionnaire is based on 20 questions related to routine activities with a grading system ranging from 0 to 3 (0: no difficulty, 1: moderate difficulty, 2: severe difficulty, 3: total incapacity). A global score between 0 point to 60 points is established. a higher HAQ score means a worse outcome | once time, Baseline |
| Correlation between global olfactory score measured with ETOC score and the rhinologic quality of life score measured with the sinonasal outcome test 22) | The ETOC score ranges from 0 to 32 points ( as previously described ). A higher score means a better outcome. The sinonasal outcome test 22 is based on 22 questions with a grading from 0 to 5 ( 0: no probem, 1: very mild problem, 2: mild problem, 3: moderate problem, 4: severe problem, 5: very severe problem). A global score between 0 and 110 points is measured. A higher score means a worse outcome. | once time, Baseline |
| Correlation between global olfactory score measured with ETOC and Hospital anxiety and Depression (HAD) scale. | The ETOC score ranges from 0 to 32 points ( as previously described ). A higher score means a better outcome. The Hospital anxiety and Depression (HAD) scale is based on 14 questions with a grading system ranging from 0 to 3. A global score between 0 and 42 is measured. A higher score means a worse outcome. | once time, Baseline |